Cara Therapeutics (CARA) Misses Q2 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. RTX
9. COF
10. GOOGL

Go back to Cara Therapeutics (CARA) Misses Q2 EPS by 6c

Cara Therapeutics Reports Second Quarter 2016 Financial Results

August 4, 2016 4:02 PM EDT

Resumed patient enrollment in adaptive pivotal trial of I.V. CR845 in post-operative pain 

Initiated adaptive Phase 2/3 trial for I.V. CR845 in dialysis patients with uremic pruritus 

Initiation of Phase 2b trial of Oral CR845 in osteoarthritis patients expected in Q3, 2016

Conference call today at 4:30 p.m. ET

STAMFORD, Conn., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ: CARA), a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively... More